Skip to main content
Premium Trial:

Request an Annual Quote

Otherwise Similar

The SARS-CoV-2 strain recently identified in the UK appears to be more easily transmitted, but otherwise is fairly similar to other viral strains, the New York Times writes.

Last month, officials in the UK reported finding a new viral strain, called B.1.1.7, in southern England that appeared to be spreading more easily, and it has since been spotted across the world in Australia, Canada, South Korea, and the US.

As the Times notes, recent analyses suggest B.1.1.7 is more transmissible — one recent analysis has suggested that it may be 56 percent more transmissible. There are some hints, the Times writes, that the strain may lead to a higher viral load among infected people, which it says could fuel the strain's easier spread, but it adds more work is needed. 

"We need to look at this evidence as preliminary and accumulating," the University of St. Andrews's Muge Cevik tells it.

The Times adds that B.1.1.7 doesn't lead to more severe disease or increased deaths than other SARS-CoV-2 strains 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.